Your browser doesn't support javascript.
COVID-19 prevalence and mortality in people with epilepsy: A nation-wide multicenter study.
Sanchez-Larsen, Alvaro; Conde-Blanco, Estefanía; Viloria-Alebesque, Alejandro; Sánchez-Vizcaíno Buendía, Cristina; Espinosa Oltra, Tatiana; Alvarez-Noval, Amanda; Aledo-Serrano, Angel; Martin-Garcia, Raquel; Ramos-Araque, María E; Campos, Dulce; Valle-Peñacoba, Gonzalo; Sierra-Gómez, Alicia; De Ceballos-Cerrajería, Pablo; Agundez-Sarasola, Marta; Khawaja, Mariam; Hampel, Kevin G; Serra-Martínez, Maria; Arbós-Barber, Clara; Gómez-Ibáñez, Asier; Villino-Boquete, Rafael; Cabezudo-García, Pablo; Rodríguez-Lavado, Ignacio; Principe, Alessandro; Sopelana-Garay, David.
  • Sanchez-Larsen A; Department of Neurology, Albacete University Hospital Complex, Albacete, Spain. Electronic address: aa.sanchezlarsen@gmail.com.
  • Conde-Blanco E; Epilepsy Program, Department of Neurology, Hospital Clínic de Barcelona, EpiCARE: European Reference Network for Epilepsy, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Viloria-Alebesque A; Instituto de Investigación Sanitaria (IIS) Aragón, Department of Neurology, Hospital General de la Defensa, Zaragoza, Spain.
  • Sánchez-Vizcaíno Buendía C; Department of Neurology, Cartagena University Hospital Complex, Murcia, Spain.
  • Espinosa Oltra T; Department of Neurology, Cartagena University Hospital Complex, Murcia, Spain.
  • Alvarez-Noval A; Department of Neurology, Ribera Povisa Hospital, Vigo, Spain.
  • Aledo-Serrano A; Epilepsy Program, Department of Neurology, Ruber International Hospital, Madrid, Spain.
  • Martin-Garcia R; Department of Neurology, Puerta de Hierro University Hospital, Madrid, Spain.
  • Ramos-Araque ME; Instituto de Investigación Biomédica de Salamanca (IBSAL), University Assistance Complex of Salamanca, Salamanca, Spain; Department of Neurology, University Assistance Complex of Salamanca, Salamanca, Spain.
  • Campos D; Department of Neurology, Valladolid University Clinical Hospital, Valladolid, Spain.
  • Valle-Peñacoba G; Department of Neurology, Valladolid University Clinical Hospital, Valladolid, Spain.
  • Sierra-Gómez A; Department of Neurology, University Assistance Complex of Salamanca, Salamanca, Spain.
  • De Ceballos-Cerrajería P; Department of Neurology, Urduliz Hospital, Bilbao, Spain.
  • Agundez-Sarasola M; Department of Neurology, Urduliz Hospital, Bilbao, Spain.
  • Khawaja M; Epilepsy Program, Department of Neurology, Hospital Clínic de Barcelona, Barcelona, Spain.
  • Hampel KG; Department of Neurology, La Fe University Hospital, Valencia, Spain.
  • Serra-Martínez M; Department of Neurology, Son Llàtzer University Hospital, Mallorca, Spain.
  • Arbós-Barber C; Department of Neurology, Son Llàtzer University Hospital, Mallorca, Spain.
  • Gómez-Ibáñez A; Department of Neurology, Clínica Universidad de Navarra, Madrid, Spain.
  • Villino-Boquete R; Department of Neurology, Clínica Universidad de Navarra, Pamplona, Spain.
  • Cabezudo-García P; Instituto de Investigación Biomédica de Málaga (IBIMA), Department of Neurology, Regional University Hospital of Málaga, Málaga, Spain.
  • Rodríguez-Lavado I; Instituto de Investigación Biomédica de Málaga (IBIMA), Department of Neurology, Regional University Hospital of Málaga, Málaga, Spain.
  • Principe A; Epilepsy Unit, Department of Neurology, Hospital del Mar, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Pompeu Fabra (UPF), Barcelona, Spain.
  • Sopelana-Garay D; Department of Neurology, Albacete University Hospital Complex, Albacete, Spain.
Epilepsy Behav ; 125: 108379, 2021 12.
Article in English | MEDLINE | ID: covidwho-1458792
ABSTRACT

BACKGROUND:

To assess the prevalence, severity, and mortality of COVID-19 in people with epilepsy (PWE) and evaluate seizure control in PWE during and after COVID-19.

METHODS:

Retrospective, observational, multicenter study conducted in 14 hospitals. Medical records of randomly selected PWE followed at neurology outpatient clinics were reviewed. Proportion of PWE with a positive test for SARS-CoV-2 during 2020 was calculated. Risk factors associated with COVID-19 and its morbimortality were evaluated.

RESULTS:

2751 PWE were included, mean age 48.8 years (18-99), 72.4% had focal epilepsy, and 35% were drug-refractory. COVID-19 prevalence in PWE was 5.53%, while in the Spanish population was 4.26%. Proportion of admissions to hospital, ICU, and deaths in PWE were 17.1%, 2%, and 4.61% of COVID-19 cases, while in Spanish population were 10.81%, 0.95%, and 2.57%, respectively. A severe form of COVID-19 occurred in 11.8%; dyslipidemia, institutionalization at long-term care facilities, intellectual disability, and older age were associated risk factors. Older age, hypertension, dyslipidemia, cardiac disease, and institutionalization were associated with mortality from COVID-19. Seizure control was stable in 90.1% of PWE during acute COVID-19, while 8.6% reported an increase in seizure frequency. During post-COVID-19 follow-up, 4.6% reported seizure control worsening.

CONCLUSIONS:

COVID-19 was moderately prevalent in PWE. One out of 5 patients required medical attention and 4.6% died due to COVID-19. Older age, dyslipidemia, institutionalization, and intellectual disability were significant risk factors associated with severe COVID-19. Seizure control remained stable during COVID-19 and throughout long-term follow-up in most PWE who contracted the infection.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Epilepsy / COVID-19 Type of study: Controlled clinical trial / Observational study / Prevalence study / Randomized controlled trials / Risk factors Limits: Aged / Humans / Middle aged Language: English Journal: Epilepsy Behav Journal subject: Behavioral Sciences / Neurology Year: 2021 Document Type: Article

Full text: Available Collection: International databases Database: MEDLINE Main subject: Epilepsy / COVID-19 Type of study: Controlled clinical trial / Observational study / Prevalence study / Randomized controlled trials / Risk factors Limits: Aged / Humans / Middle aged Language: English Journal: Epilepsy Behav Journal subject: Behavioral Sciences / Neurology Year: 2021 Document Type: Article